ICU Medical (NASDAQ:ICUI) Upgraded at Raymond James

Raymond James upgraded shares of ICU Medical (NASDAQ:ICUI) from an outperform rating to a strong-buy rating in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. The firm currently has $197.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $205.00.

ICUI has been the topic of a number of other research reports. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Monday, March 10th. Finally, KeyCorp increased their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Stock Up 2.3 %

Shares of NASDAQ ICUI opened at $143.45 on Wednesday. ICU Medical has a 52-week low of $93.36 and a 52-week high of $196.26. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -31.39 and a beta of 0.73. The stock has a 50 day moving average price of $157.61 and a 200 day moving average price of $165.08. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its holdings in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares in the last quarter. LMR Partners LLP acquired a new stake in ICU Medical in the 3rd quarter worth approximately $3,884,000. Principal Financial Group Inc. grew its position in ICU Medical by 24.6% during the 3rd quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after purchasing an additional 25,031 shares during the last quarter. MetLife Investment Management LLC increased its stake in ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after purchasing an additional 6,981 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of ICU Medical in the fourth quarter worth $556,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.